Emoxipin drops in ophthalmic practice are intended for the restoration of tissues of the organ of vision. This is a synthetic antioxidant agent that is prescribed for various eye pathologies, and with its help it is possible to prevent lipid peroxidation of cell membranes.
Vixipin is also an antioxidant that helps reduce capillary permeability, strengthen vessel walls and inhibit platelet aggregation. When it is necessary to treat eye pathologies, patients often have the question of what is better - Vixipin or Emoxipin, and which of the drugs is considered the most effective.
Release form and composition of drops
Emoxipine is available in the form of a 1% solution, and 1 ml of the drug contains 1 mg of the active component - methylethylpyridinol. The drops are packaged in a sterile 5 ml bottle. Due to the active substance, it is possible to strengthen the walls of blood vessels and achieve their expansion, as well as accelerate the resorption of small hemorrhages. In addition, the medication is effective in combating hypoxia, helps thin the blood and protects the retina from bright light.
Vixipin is available in the form of drops and contains an active substance such as methylethylpyridinol hydrochloride. The medication is a clear and colorless or slightly colored liquid.
Which is better - Viksipina and Emoksipina
In terms of the effects on the vascular system and tissues in the organ of vision, both drugs are almost identical. The main difference between Viksipin is the fact that it is produced both in 5 ml containers and in the form of small dropper tubes. This form of medication contains 0.5 ml of the drug.
In fact, soft disposable vials are more convenient to use, since after instillation they are simply thrown away. Due to this form of packaging, it is possible to achieve complete sterility of the medicine and minimize the likelihood of pathogenic microorganisms penetrating into it.
The main advantage of Emoxipin over Vixipin is its more affordable cost. Otherwise, both drugs in the form of drops do not have any significant difference in use.
Comparison of addiction between Emoxipin and Viksipin
Like safety, addiction also involves many factors that must be considered when evaluating a drug.
So, the totality of the values of such parameters as “o syndrome” in Emoxipin is quite similar to the similar values in Viksipin. Withdrawal syndrome is a pathological condition that occurs after the cessation of intake of addictive or dependent substances into the body. And resistance is understood as initial immunity to a drug; in this it differs from addiction, when immunity to a drug develops over a certain period of time. The presence of resistance can only be stated if an attempt has been made to increase the dose of the drug to the maximum possible. At the same time, Emoksipin has a fairly low value of the “syndrome”, however, the same as Viksipin.
Features of Emoxipin
Emoxipine is a synthesized drug, that is, obtained as a result of many scientific studies in pharmacological and chemical laboratories. The main component of Emoxipin is methylethylpyridinol, which gives it the following properties:
- has an antioxidant effect;
- reduces the risk of blood clots;
- improves the process of blood clotting;
- strengthens the walls of blood vessels.
With the help of Emoxipin, it is possible to quickly cope with hemorrhage, but at the same time it is possible to develop allergies, itching, burning and hyperemia of the conjunctiva. The drug must be instilled into the conjunctival sac of the eyes for 30 days, 1 drop 4 times a day. If treatment with Emoxipine is carried out in combination with other medications, then it should be used as the last one.
During therapy with Emoxipine, you should stop using contact lenses for a while. In addition, it is recommended to start driving a car half an hour after instilling the medicine into the organs of vision.
Features of Viksipin
In its composition, Vixipin is similar to Emoxipin, so with its help it is possible to achieve identical pharmacological actions. The use of drops allows you to strengthen the walls of blood vessels, prevent blood clots and thereby eliminate hemorrhage.
It is necessary to stop using this medication if a person has an individual intolerance to its constituent components during pregnancy and breastfeeding. Vixipin must be instilled for 30 days, 1 drop 4 times a day. However, if indicated, the course of therapy can be increased to six months.
Comparison of side effects of Emoxipin and Viksipin
Side effects or adverse events are any adverse medical event that occurs in a subject after administration of a drug.
Emoxipin's side effects are almost the same as Viksipin's. They both have few side effects. This implies that the frequency of their occurrence is low, that is, the indicator of how many cases of an undesirable effect of treatment are possible and registered is low. The undesirable effect on the body, the strength of influence and the toxic effect of Emoxipin are similar to Vixipin: how quickly the body recovers after taking it and whether it recovers at all.
Comparison of ease of use of Emoxipin and Viksipin
This includes dose selection taking into account various conditions and frequency of doses. At the same time, it is important not to forget about the release form of the drug; it is also important to take it into account when making an assessment.
The ease of use of Emoxipin is approximately the same as Vixipin. However, they are not convenient enough to use.
The drug ratings were compiled by experienced pharmacists who studied international research. The report is generated automatically.
Last update date: 2020-12-13 10:32:32
What are the similarities between drops?
The main active ingredient of Emoxipin and Vixipin drops is methylethylpyridinol. In addition, medicines are available in the form of a colorless solution, which is in a container of 5 or 10 ml.
Due to the active component that is present in each of the drugs, it is possible to reduce the permeability of blood vessels, strengthen them and restore the normal state of membrane cells. In addition, when using drops, it is possible to prevent blood thickening and prevent its clotting.
Vixipin eye drops 1% fl 5ml
Compound
1 ml of the drug contains: Active substance: Methylethylpyridinol hydrochloride 10.0 mg Excipients: Hydroxypropyl betadex 20.00 mg Potassium dihydrogen phosphate 10.80 mg Sodium benzoate 2.00 mg Sodium hyaluronate 1.80 mg Sodium hydrogen phosphate dihydrate 0.36 mg Disodium edetate dihydrate (trilon B) 0.20 mg Phosphoric acid solution 2 M to pH 4.0-5.0 Water for injection up to 1 ml
Pharmacokinetics
The drug quickly penetrates the eye tissue, where it is deposited and metabolized. The concentration in the tissues of the eye is higher than in the blood. Five metabolites were discovered, represented by dealkylated and conjugated products of its transformation. Metabolized in the liver. Metabolites are excreted by the kidneys. Binds to plasma proteins by an average of 42%.
Indications for use
Treatment and prevention of inflammation and burns of the cornea; - treatment of hemorrhages in the anterior chamber of the eye; - treatment and prevention of hemorrhages in the sclera in the elderly; - thrombosis of the central retinal vein and its branches; — treatment of complications of myopia; - diabetic retinopathy.
Contraindications
Individual hypersensitivity to the components of the drug, pregnancy, breastfeeding, children under 18 years of age.
Directions for use and doses
The drug is instilled into the conjunctival cavity, 1-2 drops 2-3 times a day. The duration of the course of treatment depends on the course of the disease (usually 3-30 days) and is determined by the doctor. If there are indications and the drug is well tolerated, the course of treatment can be continued for up to 6 months or repeated 2-3 times a year.
Storage conditions
At a temperature not higher than 25? C. Keep out of the reach of children.
Best before date
2 years. After opening the bottle – 1 month. Do not use after the expiration date!
special instructions
If it is necessary to use other eye drops simultaneously, the drug is instilled last, after complete absorption of the previous drug (no earlier than 15 minutes).
Description
Transparent or almost transparent, colorless or slightly colored liquid.
Conditions for dispensing from pharmacies
Dispensed by prescription.
Dosage form
Eye drops
Manufacturer and organization accepting consumer complaints
Grotex LLC, Russia 195279, St. Petersburg, Industrialny pr., 71, bldg. 2, lit. A Tel. Fax: +7 812 385 47 88 www.solopharm.com
Pharmacodynamics
The drug reduces capillary permeability, strengthens the vascular wall, stabilizes the cell membrane, inhibits platelet aggregation, reduces blood coagulability and viscosity, and has antiaggregation and antihypoxic effects.
Side effects
Possible burning sensation, itching, short-term hyperemia of the conjunctiva, local allergic reactions. If any of the side effects listed in the instructions get worse or you notice any other side effects not listed in the instructions, tell your doctor.
Use during pregnancy and breastfeeding
The use of the drug during pregnancy and breastfeeding is contraindicated
Interaction
The drug should not be mixed with other medicinal solutions
Overdose
Cases of drug overdose have not been described.
Impact on the ability to drive vehicles and operate machinery
No data.
Comparison of the safety of Emoxipin and Viksipin
The safety of a drug includes many factors.
At the same time, in Emoxipin it is quite similar to Vixipin. It is important where the drug is metabolized: drugs are excreted from the body either unchanged or in the form of products of their biochemical transformations. Metabolism occurs spontaneously, but most often involves major organs such as the liver, kidneys, lungs, skin, brain and others. When assessing the metabolism of Emoxipin, as well as Viksipin, we look at which organ is the metabolizing organ and how critical the effect on it is.
The risk-benefit ratio is when the prescription of a drug is undesirable, but justified under certain conditions and circumstances, with the obligatory observance of caution in use. At the same time, Emoxipin does not have any risks when used, just like Viksipin.
Also, when calculating safety, it is taken into account whether only allergic reactions occur or possible dysfunction of the main organs. In other matters, as well as the reversibility of the consequences of using Emoxipin and Viksipin.
